New resources Wednesday, November 06, 2024 CCTG has started a new group notification to update our network about the trials that are pending or recently activated in Canada. CCTG trials in development update will be distributed quarterly in an email to centres then posted in the group newsletter and on our social media channels. Looking for information between the quarterly updates? Not to worry, for the most recent updates and stories of recently opened CCTG trials please visit: https://www.ctg.queensu.ca/public/trials-development. Coming soonBLC6 MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcerSRC8 Doxorubicin + Pembrolizumab vs Doxorubicin for Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas Next upALC9 Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)SC30 Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PTPR26 Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)ME17 LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced MelanomaBR38 Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung CancerHE2 SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinomaMD1 CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)PAC5 Lanreotide for the Prevention of Postoperative Pancreatic FistulaSC31 Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)Recently activated trialsAL6 MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML More >>ALC7 Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials More >>ALC8 Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01) More >>BR36 CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung CancerMore >>CE9 Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2) More >>ES3NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial) More >>MAC30 Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score More >>NE2 STOPNET - Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Tumours More >>PM2 Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated with Immuno-Oncotherapeutics (CAN-IMPACT-IO) More >>PR25 Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes More >>SC29 Stereotactic Body Radiotherapy (SBRT) vs Conventional Palliative Radiotherapy (CRT) for Participants with Painful Non-Spine Bone Metastases More >>VU2 STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study More >>HN13 Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer More >> If you have questions or suggestions please contact: Lisa Callahan lcallahan@ctg.queensu.ca
